NAVIGATE 24个月结果:电磁导航支气管镜在欧美37个中心用于肺部病变
NAVIGATE是一项在7国37个中心开展的单臂实用性队列研究,前瞻随访24个月,评估电磁导航支气管镜(ENB)的安全性、诊断率和使用模式。共纳入1388例受试者,气胸和支气管肺出血发生率分别为4.7%和2.7%,主要终点(需干预或住院的操作相关气胸)为3.2%,诊断率为67.8%。
要点
- ENB相关气胸发生率4.7%,需干预或住院者为3.2%,支气管肺出血为2.7%。
- 总体诊断率为67.8%(范围61.9%-70.7%),欧洲55.2%,美国69.8%。
- 对恶性肿瘤的敏感性为62.6%,肺癌临床分期I-II期占64.7%。
核心结论
- 尽管队列异质且操作技术存在地区差异,ENB并发症低,诊断率为67.8%,并可在单次操作中完成活检、分期、基准标记置入和染料标记。
研究设计与样本
- NAVIGATE为单臂实用性队列研究(NCT02410837),在7个国家37个学术和社区中心纳入受试者,前瞻随访24个月。
- 受试者使用superDimension导航系统6.3至7.1版本接受ENB操作。
- 预设主要终点为需干预或住院的操作相关气胸。
主要发现
- 共纳入1388例受试者,其中肺病变活检1329例(95.7%),基准标记置入272例(19.6%),染料标记23例(1.7%),淋巴结活检36例(2.6%)。
- 456例受试者同期接受支气管内超声引导分期。
- 气胸和支气管肺出血发生率分别为4.7%和2.7%,需干预或住院者分别为3.2%(主要终点)和1.7%。
- 呼吸衰竭发生率为0.6%。
- 诊断率为67.8%(范围61.9%-70.7%;欧洲55.2%,美国69.8%),对恶性肿瘤的敏感性为62.6%,肺癌临床分期I-II期占64.7%(欧洲55.3%,美国65.8%)。
关键数值与推荐
- 全身麻醉使用率总体78.2%,欧洲56.6%,美国81.4%。
- 径向支气管内超声使用率总体50.6%,欧洲4.0%,美国57.4%。
- 透视使用率总体85.0%,欧洲41.7%,美国91.0%。
- 快速现场评估使用率总体61.7%,欧洲17.3%,美国68.5%。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Electromagnetic navigation bronchoscopy (ENB) is a minimally invasive, image-guided approach to access lung lesions for biopsy or localization for treatment. However, no studies have reported prospective 24-month follow-up from a large, multinational, generalizable cohort. This study evaluated ENB safety, diagnostic yield, and usage patterns in an unrestricted, real-world observational design. METHODS: The NAVIGATE single-arm, pragmatic cohort study (NCT02410837) enrolled subjects at 37 academic and community sites in seven countries with prospective 24-month follow-up. Subjects underwent ENB using the superDimension navigation system versions 6.3 to 7.1. The prespecified primary end point was procedure-related pneumothorax requiring intervention or hospitalization. RESULTS: A total of 1388 subjects were enrolled for lung lesion biopsy (1329; 95.7%), fiducial marker placement (272; 19.6%), dye marking (23; 1.7%), or lymph node biopsy (36; 2.6%). Concurrent endobronchial ultrasound-guided staging occurred in 456 subjects. General anesthesia (78.2% overall, 56.6% Europe, 81.4% United States), radial endobronchial ultrasound (50.6%, 4.0%, 57.4%), fluoroscopy (85.0%, 41.7%, 91.0%), and rapid on-site evaluation use (61.7%, 17.3%, 68.5%) differed between regions. Pneumothorax and bronchopulmonary hemorrhage occurred in 4.7% and 2.7% of subjects, respectively (3.2% [primary end point] and 1.7% requiring intervention or hospitalization). Respiratory failure occurred in 0.6%. The diagnostic yield was 67.8% (range: 61.9%-70.7%; 55.2% Europe, 69.8% United States). Sensitivity for malignancy was 62.6%. Lung cancer clinical stage was I to II in 64.7% (55.3% Europe, 65.8% United States). CONCLUSIONS: Despite a heterogeneous cohort and regional differences in procedural techniques, ENB demonstrates low complications and a 67.8% diagnostic yield while allowing biopsy, staging, fiducial placement, and dye marking in a single procedure.
引用
- Folch EE, Bowling MR, Pritchett MA, et al. NAVIGATE 24-Month Results: Electromagnetic Navigation Bronchoscopy for Pulmonary Lesions at 37 Centers in Europe and the United States. J Thorac Oncol. 2021. PMID: 34973418. doi:10.1016/j.jtho.2021.12.008
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。